Baseline correlates of frailty and its association with survival in United States veterans with acute myeloid leukemia

References

• Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN Recommendations from an International Expert Panel. Blood. 2017;129(4):424–447. doi:10.1182/blood-2016-08-733196
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34. doi:10.3322/caac.21551
   PubMed Web of Science ®Google Scholar
• Mohile SG, Dale W, Somerfield MR, et al. Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO Guideline for Geriatric Oncology. J Clin Oncol. 2018;36(22):2326–2347. doi:10.1200/JCO.2018.78.8687
   PubMed Web of Science ®Google Scholar
• Wildiers H, Heeren P, Puts M, et al. International Society of Geriatric Oncology Consensus on geriatric assessment in older patients with cancer. J Clin Oncol. 2014;32(24):2595–2603. doi:10.1200/JCO.2013.54.8347
   PubMed Web of Science ®Google Scholar
• Dotan E, Walter LC, Browner IS, et al. NCCN Guidelines® insights: older adult oncology, version 1.2021. J Natl Compr Canc Netw. 2021;19(9):1006–1019. doi:10.6004/jnccn.2021.0043
   PubMed Web of Science ®Google Scholar
• Klepin HD, Geiger AM, Tooze JA, et al. Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia. Blood. 2013;121(21):4287–4294. doi:10.1182/blood-2012-12-471680
   PubMed Web of Science ®Google Scholar
• Deschler B, Ihorst G, Platzbecker U, et al. Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome. Haematologica. 2013;98(2):208–216. doi:10.3324/haematol.2012.067892
   PubMed Web of Science ®Google Scholar
• Sherman AE, Motyckova G, Fega KR, et al. Geriatric assessment in older patients with acute myeloid leukemia: a retrospective study of associated treatment and outcomes. Leuk Res. 2013;37(9):998–1003. doi:10.1016/j.leukres.2013.05.013
   PubMed Web of Science ®Google Scholar
• Klepin HD, Tooze JA, Pardee TS, et al. Effect of intensive chemotherapy on physical, cognitive, and emotional health of older adults with acute myeloid leukemia. J Am Geriatr Soc. 2016;64(10):1988–1995. doi:10.1111/jgs.14301
   PubMed Web of Science ®Google Scholar
• Cheng JJ, Tooze JA, Callahan KE, et al. Assessment of an embedded primary care-derived electronic health record (EHR) frailty index (eFI) in older adults with acute myeloid leukemia. J Geriatr Oncol. 2023;14(7):101509. doi:10.1016/j.jgo.2023.101509
   PubMed Web of Science ®Google Scholar
• Kim DH, Glynn RJ, Avorn J, et al. Validation of a claims-based frailty index against physical performance and adverse health outcomes in the health and retirement study. J Gerontol A Biol Sci Med Sci. 2019;74(8):1271–1276. doi:10.1093/gerona/gly197
   PubMed Web of Science ®Google Scholar
• Orkaby AR, Nussbaum L, Ho Y-L, et al. The burden of frailty among US veterans and its association with mortality, 2002–2012. J Gerontol A Biol Sci Med Sci. 2019;74(8):1257–1264. doi:10.1093/gerona/gly232
   PubMed Web of Science ®Google Scholar
• Cheng D, DuMontier C, Yildirim C, et al. Updating and validating the US Veterans Affairs Frailty Index: transitioning from ICD-9 to ICD-10. J Gerontol A Biol Sci Med Sci. 2021;76(7):1318–1325. doi:10.1093/gerona/glab071
   PubMed Web of Science ®Google Scholar
• Cheng D, Dumontier C, Sheikh AR, et al. Prognostic value of the Veterans Affairs Frailty Index in older patients with non-small cell lung cancer. Cancer Med. 2022;11(15):3009–3022. doi:10.1002/cam4.4658
   PubMed Web of Science ®Google Scholar
• DuMontier C, Fillmore NR, Yildirim C, et al. Contemporary analysis of electronic frailty measurement in older adults with multiple myeloma treated in the National US Veterans Affairs Healthcare System. Cancers. 2021;13(12):3053. doi:10.3390/cancers13123053
   PubMed Web of Science ®Google Scholar
• Zhu H, Razjouyan J, Yarlagadda S, et al. Electronic Frailty Index: a risk stratification tool for survival and health care outcomes in veterans with colorectal cancer. J Clin Oncol. 2022;40(28 Suppl.):375. doi:10.1200/JCO.2022.40.28_suppl.375
   Web of Science ®Google Scholar
• Price LE, Shea K, Gephart S. The Veterans Affairs’s Corporate Data Warehouse: uses and implications for nursing research and practice. Nurs Adm Q. 2015;39(4):311–318. doi:10.1097/NAQ.0000000000000118
   PubMedGoogle Scholar
• Blodgett J, Theou O, Kirkland S, et al. Frailty in NHANES: comparing the frailty index and phenotype. Arch Gerontol Geriatr. 2015;60(3):464–470. doi:10.1016/j.archger.2015.01.016
   PubMed Web of Science ®Google Scholar
• Searle SD, Mitnitski A, Gahbauer EA, et al. A standard procedure for creating a frailty index. BMC Geriatr. 2008;8(1):24. doi:10.1186/1471-2318-8-24
   PubMedGoogle Scholar
• Hoover M, Rotermann M, Sanmartin C, et al. Validation of an index to estimate the prevalence of frailty among community-dwelling seniors. Health Rep. 2013;24(9):10–17.
   PubMed Web of Science ®Google Scholar
• Pajewski NM, Williamson JD, Applegate WB, et al. Characterizing frailty status in the systolic blood pressure intervention trial. J Gerontol A Biol Sci Med Sci. 2016;71(5):649–655. doi:10.1093/gerona/glv228
   PubMed Web of Science ®Google Scholar
• Armstrong JJ, Andrew MK, Mitnitski A, et al. Social vulnerability and survival across levels of frailty in the Honolulu-Asia Aging Study. Age Ageing. 2015;44(4):709–712. doi:10.1093/ageing/afv016
   PubMed Web of Science ®Google Scholar
• Sohn M-W, Arnold N, Maynard C, et al. Accuracy and completeness of mortality data in the Department of Veterans Affairs. Popul Health Metr. 2006;4(1):2. doi:10.1186/1478-7954-4-2
   PubMedGoogle Scholar
• Lai C, Conway O, Lee M, et al. Deficit Accumulation Frailty Index (DAFI) scores and acute myeloid leukemia outcomes. J Clin Oncol. 2022;40(16 Suppl.):12040. doi:10.1200/JCO.2022.40.16_suppl.12040
   Web of Science ®Google Scholar
• Patel BG, Luo S, Wildes TM, et al. Frailty in older adults with multiple myeloma: a study of US veterans. J Clin Oncol Clin Cancer Inform. 2020;4:117–127. doi:10.1200/CCI.19.00094
   PubMed Web of Science ®Google Scholar
• Cohen HJ, Smith D, Sun CL, et al. Frailty as determined by a comprehensive geriatric assessment‐derived deficit‐accumulation index in older patients with cancer who receive chemotherapy. Cancer. 2016;122(24):3865–3872. doi:10.1002/cncr.30269
   PubMed Web of Science ®Google Scholar
• Saad M, Loh KP, Tooze JA, et al. Geriatric assessment and survival among older adults receiving postremission therapy for acute myeloid leukemia. Blood. 2020;136(23):2715–2719. doi:10.1182/blood.2020005498
   PubMed Web of Science ®Google Scholar
• Rockwood K, Theou O. Using the clinical frailty scale in allocating scarce health care resources. Can Geriatr J. 2020;23(3):210–215.
   PubMed Web of Science ®Google Scholar
• Hennis RY, Seligman B, Fonseca Valencia C, et al. Validation of the electronic Veterans Affairs Frailty Index against clinician frailty assessment. J Am Geriatr Soc. 2023;71(S1): S1–S398.
   Google Scholar
• DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617–629. doi:10.1056/NEJMoa2012971
   PubMed Web of Science ®Google Scholar
• Wei AH, Montesinos P, Ivanov V, et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood. 2020;135(24):2137–2145. doi:10.1182/blood.2020004856
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Ravandi F, O'Brien S, et al. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood. 2010;116(22):4422–4429. doi:10.1182/blood-2010-03-276485
   PubMed Web of Science ®Google Scholar
• Khalaf D, Berg T, Hillis C, et al. AML-303: systematic review of frailty assessment tools for elderly patients with acute myeloid leukemia. Clin Lymph Myeloma Leuk. 2020;20:S200. doi:10.1016/S2152-2650(20)30751-5
   Google Scholar
• Herold T, Rothenberg-Thurley M, Grunwald VV, et al. Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia. Leukemia. 2020;34(12):3161–3172. doi:10.1038/s41375-020-0806-0
   PubMed Web of Science ®Google Scholar
• Bataller A, Garrido A, Guijarro F, et al. European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol. Blood Adv. 2022;6(4):1193–1206. doi:10.1182/bloodadvances.2021005585
   PubMed Web of Science ®Google Scholar
• Döhner K, Thiede C, Jahn N, et al. Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia. Blood. 2020;135(5):371–380. doi:10.1182/blood.2019002697
   PubMed Web of Science ®Google Scholar
• Harada Y, Nagata Y, Kihara R, et al. Prognostic analysis according to the 2017 ELN risk stratification by genetics in adult acute myeloid leukemia patients treated in the Japan Adult Leukemia Study Group (JALSG) AML201 study. Leuk Res. 2018;66:20–27. doi:10.1016/j.leukres.2018.01.008
   PubMed Web of Science ®Google Scholar
• Eisfeld A-K, Kohlschmidt J, Mims A, et al. Additional gene mutations. Refine the 2017 European LeukemiaNet classification in adult patients with de novo acute myeloid leukemia aged <60 years. Leukemia. 2020;34(12):3215–3227. doi:10.1038/s41375-020-0872-3
   PubMed Web of Science ®Google Scholar
• Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an International Expert Panel on behalf of the ELN. Blood. 2022;140(12):1345–1377. doi:10.1182/blood.2022016867
   PubMed Web of Science ®Google Scholar
• Döhner H, Pratz KW, DiNardo CD, et al. ELN risk stratification is not predictive of outcomes for treatment-naïve patients with acute myeloid leukemia treated with venetoclax and azacitidine. Blood. 2022;140(Suppl. 1):1441–1444. doi:10.1182/blood-2022-169509
   Google Scholar
• Victoria VP, Maja R-T, Maria CS, et al. Genetics of acute myeloid leukemia in the elderly: mutation spectrum and clinical impact in intensively treated patients aged 75 years or older. Haematologica. 2018;103(11):1853–1861.
   PubMed Web of Science ®Google Scholar
• Medeiros BC, Othus M, Fang M, et al. Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience. Blood. 2010;116(13):2224–2228. doi:10.1182/blood-2010-02-270330
   PubMed Web of Science ®Google Scholar
• Metzeler KH, Herold T, Rothenberg-Thurley M, et al. Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia. Blood. 2016;128(5):686–698. doi:10.1182/blood-2016-01-693879
   PubMed Web of Science ®Google Scholar
• Jaiswal S, Ebert BL. Clonal hematopoiesis in human aging and disease. Science. 2019;366(6465):eaan4673. doi:10.1126/science.aan4673
   PubMed Web of Science ®Google Scholar
• Trifunovic A, Wredenberg A, Falkenberg M, et al. Premature ageing in mice expressing defective mitochondrial DNA polymerase. Nature. 2004;429(6990):417–423. doi:10.1038/nature02517
   PubMed Web of Science ®Google Scholar
• Loh KP, Tooze JA, Nicklas BJ, et al. Inflammatory biomarkers, geriatric assessment, and treatment outcomes in acute myeloid leukemia. J Geriatr Oncol. 2020;11(3):410–416. doi:10.1016/j.jgo.2019.03.014
   PubMed Web of Science ®Google Scholar
• Chaudhury S, O'Connor C, Cañete A, et al. Age-specific biological and molecular profiling distinguishes paediatric from adult acute myeloid leukaemias. Nat Commun. 2018;9(1):5280. doi:10.1038/s41467-018-07584-1
   PubMedGoogle Scholar
• Gordon EH, Peel NM, Samanta M, et al. Sex differences in frailty: a systematic review and meta-analysis. Exp Gerontol. 2017;89:30–40. doi:10.1016/j.exger.2016.12.021
   PubMed Web of Science ®Google Scholar
• Levit LA, Kaltenbaugh MW, Magnuson A, et al. Challenges and opportunities to developing a frailty index using electronic health record data. J Geriatr Oncol. 2021;12(5):851–854. doi:10.1016/j.jgo.2021.02.008
   PubMed Web of Science ®Google Scholar